by admin | Nov 9, 2023 | Press Releases
ENB-003 in combination with KEYTRUDA® (pembrolizumab) demonstrated encouraging objective responses, disease control and progression-free survival in patients with metastatic platinum refractory/resistant ovarian cancer (PROC) Encouraging results support further...
by admin | Jul 21, 2023 | Press Releases
ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint The ENB-003 in combination with KEYTRUDA® (pembrolizumab) was well tolerated Promising preliminary efficacy signals with 33% disease...
by admin | Nov 9, 2022 | Press Releases
Friday, November 4, 2022 7:00 AM ENB is developing first in class small molecule ENB-003 to selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / November 4, 2022 / ENB Therapeutics, Inc., a biotechnology company...
by admin | May 25, 2022 | Press Releases
Tuesday, May 24, 2022 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=702335 ENB-003 is a first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE / May 24, 2022 / ENB...
by admin | Feb 8, 2021 | Press Releases
Monday, February 1, 2021 8:00 AM https://www.accesswire.com/viewarticle.aspx?id=626781 ENB-003 is the Company’s first in class small molecule therapeutic selectively targeting the ETB receptor – a novel immune checkpoint NEW YORK, NY / ACCESSWIRE /...
